• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.13% Nasdaq Up0.14%

    Prothena Corporation plc (PRTA)

    -NasdaqGS
    46.06 Down 1.49(3.13%) May 26, 4:00PM EDT
    ProfileGet Profile for:
    Prothena Corporation plc
    Adelphi Plaza
    Upper George's Street
    Dublin, A96 T927
    Ireland - Map
    Phone: 353 1 236 2500
    Fax: 353 1 902 3510
    Website: http://www.prothena.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:66

    Business Summary 

    Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion in Ireland. It is developing antibody-based product candidates that include NEOD001, a humanized monoclonal antibody for the treatment of AL amyloidosis and persistent organ dysfunction diseases; PRX002 for treating Parkinson’s disease and other related synucleinopathies; and PRX003, a monoclonal antibody for the treatment of psoriasis and other inflammatory diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Prothena Corporation plc

    Corporate Governance 
    Prothena Corporation plc’s ISS Governance QuickScore as of May 1, 2016 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Dale B. Schenk Ph.D., 59
    Chief Exec. Officer, Pres and Director
    790.00K0.00
    Mr. Tran B. Nguyen M.B.A., 42
    Chief Financial Officer
    488.00K0.00
    Mr. Gene G. Kinney Ph.D., 47
    Chief Scientific Officer and Head of R&D
    512.00K0.00
    Mr. Arthur W. Homan J.D., 57
    Chief Legal Officer
    457.00K0.00
    Dr. Martin Koller M.D., M.P.H., 65
    Chief Medical Officer
    493.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders